Novartis AG Receivables 2012-2026 | NVS

Novartis AG receivables for the quarter ending March 31, 2026 were $9.602B, a 10.05% increase year-over-year.

  • Novartis AG receivables for 2025 were $9.142B, a 20.99% increase from 2024.
  • Novartis AG receivables for 2024 were $7.556B, a 0.31% increase from 2023.
  • Novartis AG receivables for 2023 were $7.533B, a 9.61% decline from 2022.

Novartis AG Receivables 2012-2026 | NVS

  • Novartis AG receivables for 2025 were $9.142B, a 20.99% increase from 2024.
  • Novartis AG receivables for 2024 were $7.556B, a 0.31% increase from 2023.
  • Novartis AG receivables for 2023 were $7.533B, a 9.61% decline from 2022.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$887.6B
Johnson & Johnson (JNJ)$574.4B
AbbVie (ABBV)$367.7B
Roche Holding AG (RHHBY)$318.8B
Merck (MRK)$299.9B
Novo Nordisk (NVO)$167.5B
Pfizer (PFE)$153.1B
Sanofi (SNY)$114B
Bayer (BAYRY)$46.2B
Innoviva (INVA)$1.8B